Bibliographic Details
| Title: |
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug |
| Authors: |
Alan Faraj, Tom Knudsen, Shraddha Desai, Linda Neuman, Grant E. Blouse, Ulrika S. H. Simonsson |
| Source: |
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 12, Pp 1628-1637 (2022) |
| Publisher Information: |
Wiley, 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Therapeutics. Pharmacology |
| Subject Terms: |
Therapeutics. Pharmacology, RM1-950 |
| More Details: |
Abstract Marzeptacog alfa (activated) (MarzAA) is an activated recombinant human FVII (rFVIIa) variant developed as subcutaneous (s.c.) administration for the treatment or prevention of bleeding episodes in patients with hemophilia A (HA) or hemophilia B (HB) with inhibitors and other rare bleeding disorders. Population pharmacokinetic (PK) modeling was applied for dose selection for a pivotal phase III clinical trial evaluating s.c. MarzAA for episodic treatment of spontaneous or traumatic bleeding episodes. The population PK model used MarzAA intravenous and s.c. data from previously completed clinical trials in patients with HA/HB with or without inhibitors. Based on the model, clinical trial simulations were performed to predict MarzAA exposure after different dosing regimens. The exposure target was identified using an exposure‐matching strategy with a wild‐type rFVIIa but adjusting for the difference in potency between the two compounds. Simulations demonstrated a sufficient absorption rate and prolonged exposure following a single 60 μg/kg dose leading to 51% and 70% of the population reaching levels above the target after 3 and 6 h, respectively. According to the phase III protocol, if a second dose was required after 3 h because of a lack of efficacy, 90% of the population was observed to be above target 6 h after the initial dose. The model‐informed drug development approach integrated information from several trials and guided dose selection in the pivotal phase III clinical trial for episodic treatment of an acute bleeding event in individuals with HA or HB with inhibitors without the execution of a phase II trial for that indication. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2163-8306 |
| Relation: |
https://doaj.org/toc/2163-8306 |
| DOI: |
10.1002/psp4.12872 |
| Access URL: |
https://doaj.org/article/ce8d06664ffc40fd91a8527d8fc691ac |
| Accession Number: |
edsdoj.8d06664ffc40fd91a8527d8fc691ac |
| Database: |
Directory of Open Access Journals |
